Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Study of MK-5475 in Adults with Pulmonary Arterial Hypertension
2022-500877-15-00Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing MK-5475 with Placebo (2 arms). Primary endpoints: Change from Baseline in Pulmonary Vascular Resistance at 12 Weeks (Phase 2 Cohort) and Change from Baseline in 6-Minute Walk Distance at 12 Weeks (Phase 3 Cohort). Started Jun 2021; status: completed.
02
Drugs
frespaciguat
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2022-500877-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500877-15-00.